Next Article in Journal
Using pet-ct to Reduce Futile Thoracotomy Rates in Non-Small-Cell Lung Cancer: A Population-Based Review
Previous Article in Journal
Cost-Effectiveness of Pazopanib in Advanced Soft-Tissue Sarcoma in Canada
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 21
Issue 6
10.3747/co.21.2051
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Aprepitant and Granisetron for the Prophylaxis of Radiotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Radiotherapy for Bone Metastases: A Prospective Pilot Study

by
K. Dennis
1,*,
C. De Angelis
2,
F. Jon
3,
N. Lauzon
3,
M. Pasetka
2,
L. Holden
3,
E. Barnes
3,
C. Danjoux
3,
A. Sahgal
3,
M. Tsao
3 and
E. Chow
3
1
Division of Radiation Oncology, The Ottawa Hospital and University of Ottawa, and The Ottawa Hospital Research Institute, Ottawa, ON, Canada
2
Department of Pharmacy, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
3
Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(6), 760-767; https://doi.org/10.3747/co.21.2051
Submission received: 14 September 2014 / Revised: 6 October 2014 / Accepted: 2 November 2014 / Published: 1 December 2014

Abstract

Purpose: We evaluated the novel combination of aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting (RINV) among patients receiving moderately-emetogenic radiotherapy for thoracolumbar bone metastases. Methods: In this single-centre two-arm nonrandomized prospective pilot study, patients undergoing single-fraction radiotherapy (8 Gy) received aprepitant 125 mg and granisetron 2 mg on the day of radiotherapy and aprepitant 80 mg on each of the first 2 days after the day of radiotherapy. Patients undergoing multiple-fraction radiotherapy (20 Gy in 5 fractions) received aprepitant 125 mg on day 1 of radiotherapy, aprepitant 80 mg on days 3 and 5 of radiotherapy, and granisetron 2 mg on every day of radiotherapy. Symptoms and total medication intake were recorded daily during the acute phase (day 1 of radiotherapy until the first day after the last day of radiotherapy), and the delayed phase (days 2–10 after the last day of radiotherapy). Control of vomiting, retching, and nausea was defined as no symptoms and no use of rescue medication. Results: Control rates for single-fraction patients (n = 13) were 100% for acute nausea, 62% for delayed nausea, 100% for acute vomiting and retching, and 85% for delayed vomiting and retching. Control rates for multiple-fraction patients (n = 6) were 67% for acute nausea, 83% for delayed nausea, 67% for acute vomiting and retching, and 83% for delayed vomiting and retching. No grade 3 or 4 toxicities attributable to the study intervention were observed. Conclusions: The combination of aprepitant and granisetron was safe and efficacious for the prophylaxis of RINV after both single- and multiple-fraction moderately emetogenic radiotherapy for thoracolumbar bone metastases. Our results require confirmation in a larger population.
Keywords: antiemetic; aprepitant; granisetron; nausea; vomiting; radiotherapy antiemetic; aprepitant; granisetron; nausea; vomiting; radiotherapy

Share and Cite

MDPI and ACS Style

Dennis, K.; De Angelis, C.; Jon, F.; Lauzon, N.; Pasetka, M.; Holden, L.; Barnes, E.; Danjoux, C.; Sahgal, A.; Tsao, M.; et al. Aprepitant and Granisetron for the Prophylaxis of Radiotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Radiotherapy for Bone Metastases: A Prospective Pilot Study. Curr. Oncol. 2014, 21, 760-767. https://doi.org/10.3747/co.21.2051

AMA Style

Dennis K, De Angelis C, Jon F, Lauzon N, Pasetka M, Holden L, Barnes E, Danjoux C, Sahgal A, Tsao M, et al. Aprepitant and Granisetron for the Prophylaxis of Radiotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Radiotherapy for Bone Metastases: A Prospective Pilot Study. Current Oncology. 2014; 21(6):760-767. https://doi.org/10.3747/co.21.2051

Chicago/Turabian Style

Dennis, K., C. De Angelis, F. Jon, N. Lauzon, M. Pasetka, L. Holden, E. Barnes, C. Danjoux, A. Sahgal, M. Tsao, and et al. 2014. "Aprepitant and Granisetron for the Prophylaxis of Radiotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Radiotherapy for Bone Metastases: A Prospective Pilot Study" Current Oncology 21, no. 6: 760-767. https://doi.org/10.3747/co.21.2051

APA Style

Dennis, K., De Angelis, C., Jon, F., Lauzon, N., Pasetka, M., Holden, L., Barnes, E., Danjoux, C., Sahgal, A., Tsao, M., & Chow, E. (2014). Aprepitant and Granisetron for the Prophylaxis of Radiotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Radiotherapy for Bone Metastases: A Prospective Pilot Study. Current Oncology, 21(6), 760-767. https://doi.org/10.3747/co.21.2051

Article Metrics

Back to TopTop